Oleg Stroganov

Oleg Stroganov

Auto-generated profile, based on publicly available information

Oleg Stroganov

Rancho Biosciences, Rancho Santa Fe, CA 92067, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2021 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
VSVishal B Siramshetty
Vishal B Siramshetty
IGIvan Grishagin
Ivan Grishagin
ÐNÐắc-Trung Nguyễn
Ðắc-Trung Nguyễn
TPTyler Peryea
Tyler Peryea
YSYulia Skovpen
Yulia Skovpen
NSNoel T Southall
Noel T Southall
The United States has a complex regulatory scheme for marketing drugs. Understanding drug regulatory status is a daunting task that requires integrating data from many sources from the United States Food and Drug Administration (FDA), US government publications, and other processes related to drug development. At NCATS, we created Inxight Drugs (https://drugs.ncats.io), a web resource that attempts to address this challenge in a systematic manner. NCATS Inxight Drugs incorporates and unifies a wealth of data, including those supplied by the FDA and from independent public sources. The database offers a substantial amount of manually curated literature data unavailable from other sources. Currently, the database contains 125 036 product ingredients, including 2566 US approved drugs, 6242 marketed drugs, and 9684 investigational drugs. All substances are rigorously defined according to the ISO 11238 standard to comply with existing regulatory standards for unique drug substance identification. A special emphasis was placed on capturing manually curated and referenced data on treatment modalities and semantic relationships between substances. A supplementary resource ‘Novel FDA Drug Approvals’ features regulatory details of newly approved FDA drugs. The database is regularly updated using NCATS Stitcher data integration tool that automates data aggregation and supports full data access through a RESTful API.

16 December 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
OSOleg Stroganov
Oleg Stroganov
AFAlena Fedarovich
Alena Fedarovich
EWEmily Wong
Emily Wong
YSYulia Skovpen
Yulia Skovpen
EPElena Pakhomova
Elena Pakhomova
JBJulie Bryant
Julie Bryant
Objective: The UK Biobank provides a rich collection of longitudinal clinical data coming from different healthcare providers and sources in England, Wales, and Scotland. Although extremely valuable and available to a wide research community, the heterogeneous dataset contains inconsistent medical terminology that is either aligned to several ontologies within the same category or unprocessed. To make these data useful to a research community, data cleaning, curation, and standardization are needed. Significant efforts to perform data reformatting, mapping to any selected ontologies (such as SNOMED-CT) and harmonization are required from any data user to integrate UK Biobank hospital inpatient and self-reported data, data from various registers with primary care (GP) data. The integrated clinical data would provide a more comprehensive picture of one’s medical history. Materials and methods: We evaluated several approaches to map GP clinical Read codes to International Classification of Diseases (ICD) and Systematized Nomenclature of Medicine Clinical Terms (SNOMED CT) terminologies. The results were compared, mapping inconsistencies were flagged, a quality category was assigned to each mapping to evaluate overall mapping quality. Results: We propose a curation and data integration pipeline for harmonizing diagnosis. We also report challenges identified in mapping Read codes from UK Biobank GP tables to ICD and SNOMED CT. Discussion and conclusion: Some of the challenges–the lack of precise one-to-one mapping between ontologies or the need for additional ontology to fully map terms–are general reflecting trade-offs to be made at different steps. Other challenges are due to automatic mapping and can be overcome by leveraging existing mappings, supplemented with automated and manual curation.

11 January 2024 in Biology Methods and Protocols
Verified
Journal Article
Open access
PDF file
OSOleg Stroganov
Oleg Stroganov
ASAmber Schedlbauer
Amber Schedlbauer
ELEmily Lorenzen
Emily Lorenzen
AKAlex Kadhim
Alex Kadhim
ALAnna Lobanova
Anna Lobanova
JGJill R Glausier
Jill R Glausier
The aim of this study was to make unstructured neuropathological data, located in the NeuroBioBank (NBB), follow Findability, Accessibility, Interoperability, and Reusability principles and investigate the potential of large language models (LLMs) in wrangling unstructured neuropathological reports. By making the currently inconsistent and disparate data findable, our overarching goal was to enhance research output and speed. The NBB catalog currently includes information from medical records, interview results, and neuropathological reports. These reports contain crucial information necessary for conducting an in-depth analysis of NBB data but have multiple formats that vary across different NBB biorepositories and change over time. In this study, we focused on a subset of 822 donors with Parkinson’s disease (PD) from seven NBB biorepositories. We developed a data model with combined Brain Region and Pathological Findings data at its core. This approach made it easier to build an extraction pipeline and was flexible enough to convert resulting data to Common Data Elements, a standardized data collection tool used by the neuroscience community to improve consistency and facilitate data sharing across studies. This pilot study demonstrated the potential of LLMs in structuring unstructured neuropathological reports of PD patients available in the NBB. The pipeline enabled successful extraction of detailed tissue-level (microscopic) and gross anatomical (macroscopic) observations, along with staging information from pathology reports, with extraction quality comparable to manual curation results. To our knowledge, this is the first attempt to automatically standardize neuropathological information at this scale. The collected data have the potential to serve as a valuable resource for PD researchers, facilitating integration with clinical information and genetic data (such as genome-wide genotyping and whole-genome sequencing) available through the NBB, thereby enabling a more comprehensive understanding of the disease.

21 January 2020 in Journal of Computer-Aided Molecular Design
Verified
Journal Article
Closed access
PDF file
OSOleg V. Stroganov
Oleg V. Stroganov
FNFedor N. Novikov
Fedor N. Novikov
MMMichael G. Medvedev
Michael G. Medvedev
ADArtem O. Dmitrienko
Artem O. Dmitrienko
IGIgor Gerasimov
Igor Gerasimov
GCGhermes G. Chilov
Ghermes G. Chilov

25 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
PRPolina Rusina
Polina Rusina
EGErik Gandalipov
Erik Gandalipov
YAYana Abdusheva
Yana Abdusheva
MPMaria Panova
Maria Panova
ABAlexandra Burdenkova
Alexandra Burdenkova
Fedor NovikovFedor Novikov
Fedor Novikov
The rational design of cyclin-dependent protein kinase (CDK) inhibitors presumes the development of approaches for accurate prediction of selectivity and the activity of small molecular weight anticancer drug candidates. Aiming at attenuation of general toxicity of low selectivity compounds, we herein explored the new chemotype of imidazole-4-N-acetamide substituted derivatives of the pan-CDK inhibitor PHA-793887. Newly synthesized compounds 1–4 containing an aliphatic methyl group or aromatic radicals at the periphery of the scaffold were analyzed for the prediction of relative free energies of binding to CDK1, -2, -5, and -9 using a protocol based on non-equilibrium (NEQ) thermodynamics. This methodology allows for the demonstration of a good correlation between the calculated parameters of interaction of 1–4 with individual targets and the values of inhibitory potencies in in vitro kinase assays. We provide evidence in support of NEQ thermodynamics as a time sparing, precise, and productive approach for generating chemical inhibitors of clinically relevant anticancer targets.

1 July 2015 in Mendeleev Communications
Verified
Journal Article
Closed access
AZAlexey A. Zeifman
Alexey A. Zeifman
VSVictor Stroylov
Victor Stroylov
ITIlya Yu. Titov
Ilya Yu. Titov
Fedor NovikovFedor Novikov
Fedor Novikov
OSOleg V. Stroganov
Oleg V. Stroganov
GCGhermes G. Chilov
Ghermes G. Chilov